jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Buttock mass - Large Biopsy 3-6 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy of large buttock lesion.

₹666₹951

30% OFF

Buttock Mass - Large Biopsy 3-6 cm

  • Why is it done?
    • Obtain tissue diagnosis of a buttock mass measuring 3-6 cm in size to determine the nature and etiology of the lesion
    • Differentiate between benign lesions (lipoma, cyst, hemangioma) and malignant tumors (soft tissue sarcoma, melanoma, metastatic disease)
    • Evaluate masses that are enlarging, symptomatic, or clinically suspicious for malignancy despite imaging findings
    • Confirm suspected diagnosis when imaging studies (ultrasound, MRI, CT) are inconclusive
    • Provide material for histopathologic examination, immunohistochemistry, and molecular testing when indicated
    • Guide treatment planning and surgical management decisions
  • Normal Range
    • Normal/Benign Findings: Absence of malignant cells, tumor infiltration, or atypical features Benign histologic patterns consistent with lipoma, cyst, fibroma, hemangioma, or other common soft tissue lesions
    • Negative Result: No evidence of malignancy Normal, inflammatory, or benign pathologic tissue
    • Units of Measurement: Tissue specimen: qualitative histopathologic description Size category: 3-6 cm (large biopsy classification)
    • What Normal Means: Benign lesion without malignant potential Low risk for recurrence or metastatic spread Conservative management or simple excision typically appropriate
  • Interpretation
    • Benign Diagnoses: Lipoma: mature adipose tissue, most common soft tissue mass Cyst: fluid-filled cavity with epithelial or fibrous lining Hemangioma: benign vascular lesion Fibroma: benign fibrous tissue proliferation Ganglion cyst: myxoid cyst arising from joint or tendon sheath
    • Malignant Diagnoses: Liposarcoma: malignant adipose tissue tumor Leiomyosarcoma: smooth muscle malignancy Fibrosarcoma: fibroblastic malignancy Melanoma: malignant melanocytic lesion Metastatic carcinoma: secondary malignant deposit Lymphoma: malignant lymphoid proliferation
    • Atypical/Borderline Results: Atypical lipomatous tumor (ALT): may require molecular testing (MDM2/CDK4 amplification) Borderline/indeterminate lesions: may need repeat biopsy or complete excision High-grade dysplasia: increased malignant potential requiring close follow-up
    • Factors Affecting Interpretation: Adequacy of tissue sample Biopsy site (central vs peripheral location) Crush artifact or thermal artifact from procedure Inflammatory changes masking underlying pathology Tumor heterogeneity with variable cellularity Prior radiation or chemotherapy effects
    • Clinical Significance Patterns: Grade I (low-grade): slow growth, lower metastatic risk Grade II (intermediate): moderate growth rate and biological behavior Grade III (high-grade): rapid growth, high metastatic potential Stage determines treatment urgency and surgical margins required
  • Associated Organs
    • Primary Anatomic Location: Soft tissues of gluteal region Muscles: gluteus maximus, gluteus medius Subcutaneous and deep fascial layers Adjacent structures: sacrum, hip joint
    • Organ Systems Involved: Integumentary system (skin, subcutaneous tissue) Musculoskeletal system (skeletal muscle, connective tissue) Vascular and lymphatic systems (if hemangioma or lymphoma)
    • Associated Diseases/Conditions: Soft tissue sarcoma (various histologic types) Cutaneous and subcutaneous melanoma Lipomatosis and multiple lipomas Neurofibromatosis type 1 (increased sarcoma risk) Prior malignancy with metastatic disease Lymphoproliferative disorders Chronic inflammatory conditions
    • Potential Complications/Risks from Abnormal Results: Rapid local invasion with functional impairment Metastatic spread to regional lymph nodes, lungs, bones, liver Compression of adjacent structures (nerves, blood vessels) Pain and mobility restriction Increased morbidity and mortality if malignancy confirmed Need for aggressive surgical resection with wide margins Potential need for adjuvant chemotherapy or radiation
  • Follow-up Tests
    • If Benign Diagnosis Confirmed: Clinical follow-up examination at 3-6 month intervals Surveillance imaging (ultrasound or MRI) only if symptomatic or changing Excision or reassurance depending on lesion type and patient preference
    • If Malignancy Confirmed: Complete imaging staging: CT chest/abdomen/pelvis or PET-CT Regional lymph node assessment (imaging or ultrasound) Sentinel lymph node biopsy (if melanoma) Margins reassessment and wide local excision planning Multidisciplinary tumor board review Sentinel node biopsy in selected cases
    • Molecular/Immunohistochemical Testing: MDM2/CDK4 FISH for atypical lipomatous tumor confirmation Immunohistochemistry for prognostic markers Molecular testing for specific sarcoma translocations (EWSR1, FUS, etc.) Tumor genetics panel for therapeutic planning
    • Ongoing Monitoring for Malignant Cases: Physical examination every 3 months for first 2 years, then every 6 months Imaging surveillance based on grade and histology Dermatology follow-up if melanoma Oncology consultation for systemic therapy options Wound care and surgical site follow-up
    • Complementary Tests: MRI for better soft tissue characterization and surgical planning Ultrasound for initial characterization and guidance Flow cytometry if lymphoma suspected Skin examination and dermoscopy if melanoma Blood tests (LDH, CBC) for prognostic information
  • Fasting Required?
    • Fasting Requirement: NO
    • Patient Preparation Requirements: Fasting is NOT necessary for this biopsy procedure Normal diet and hydration may be maintained Can take routine morning medications Discontinue aspirin and NSAIDs 7-10 days prior if possible Discontinue anticoagulants (warfarin, apixaban) 3-7 days prior Consult physician if on anticoagulation therapy Discontinue antiplatelet agents after physician approval
    • Pre-Procedure Instructions: Wear loose, comfortable clothing Mark the lesion location with patient Skin cleansing/antisepsis at biopsy site Position patient prone or lateral depending on mass location Confirm informed consent Baseline imaging available for guidance (ultrasound or CT)
    • Anesthesia/Sedation: Local anesthesia required at biopsy site Conscious sedation may be offered at some facilities Nothing by mouth (NPO) 2-4 hours prior if sedation planned Arrange transportation if sedation is used
    • Post-Procedure Care: Keep bandage/dressing clean and dry for 24-48 hours Avoid strenuous activity for 1-2 weeks Mild analgesia (acetaminophen) for discomfort as needed Avoid sitting pressure on biopsy site if possible Monitor for signs of infection (fever, increased redness, drainage) Follow wound care instructions provided Results typically available within 5-10 business days

How our test process works!

customers
customers